Comparison of Bronchodilator Response From Three Different Aerosol Delivery Methods in Patients With COPD Using Hyperpolarized Xe 129 MRI Ventilation Imaging - Trial NCT06271408
Access comprehensive clinical trial information for NCT06271408 through Pure Global AI's free database. This Phase 1 trial is sponsored by Polarean, Inc. and is currently Recruiting. The study focuses on Chronic Obstructive Pulmonary Disease. Target enrollment is 6 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution
Interventional
drug
Sponsor & Location
Polarean, Inc.
Timeline & Enrollment
Phase 1
Feb 01, 2024
Apr 01, 2024
Primary Outcome
Ventilation Defect Percent
Summary
The goal of this clinical trial is to compare responses to bronchodilator treatment delivered
 by three different aerosol delivery methods in patients with chronic obstructive pulmonary
 disease (COPD). The main question it aims to answer is whether there are differences in lung
 ventilation following treatment with each of the three methods as measured using
 hyperpolarized Xe 129 with MRI.
 
 Participants will:
 
 Receive a standard dose of albuterol delivered using each of 3 aerosol delivery devices. In
 total, participants will receive three treatments separated by at least 1 week each.
 
 Following each treatment, participants will have inhale an MRI contrast agent called
 hyperpolarized Xe 129 and will have images of their lungs taken with an MRI.
 
 Researchers will compare the different lung images taken after each treatment to see if there
 are differences in the distribution of air in the lungs (known as ventilation).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06271408
Non-Device Trial